OVID Stock Soars 40% in 2 Sessions on Preliminary Drug Results
OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study. Positive Momentum Ovid Therapeutics ... [Read]
OVID Stock Extends Rally: Jumps 50% in a Week
OVID stock continues to move higher for the fourth straight session and jumps another 10% this morning after Ovid Therapeutics’ (NASDAQ:OVID) product “OV101” won orphan drug designation by the European Commission. Another Key Announcement Ovid ... [Read]